Glioblastoma Multiforme Therapeutics Market in Asia-Pacific Region to Post High Growth to Reach $105.8m by 2020, Reveals New Report

Lewes, DE -- (SBWIRE) -- 08/27/2014 -- The Glioblastoma Multiforme (GBM) therapeutics market in the four Asia-Pacific (APAC) markets of Australia, China, India and Japan was worth $49.4m in 2013, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 11.5% to $105.8m by 2020. Japan was the largest of these markets in 2013, valued at $23.8m, equivalent to a share of 48%, closely followed by China at $19.7m or 40%. This significant expected growth is due to the probable approval and market entries of Rindopepimut (CDX-110), Cotara (TNT-1) and Avastin (bevacizumab) in some of the APAC regions during the forecast period.